



## PEDIATRIC BLOOD AND MARROW TRANSPLANT PROGRAM

**DOCUMENT NUMBER:**

**DOCUMENT TITLE:**

**DOCUMENT NOTES:**

### Document Information

**Revision:**

**Vault:**

**Status:**

**Document Type:**

### Date Information

**Creation Date:**

**Release Date:**

**Effective Date:**

**Expiration Date:**

### Control Information

**Author:**

**Owner:**

**Previous Number:**

**Change Number:**

**PBMT-GEN-031**  
**ADMINISTRATION OF MYCOPHENOLATE MOFETIL (CELLCEPT)**

**1 PURPOSE**

- 1.1 To outline the procedure required for administration of mycophenolate mofetil (CellCept). Responsibilities of the nursing staff for administering and monitoring adverse reactions to mycophenolate mofetil are described.

**2 INTRODUCTION**

- 2.1 Mycophenolate mofetil (CellCept) is a medication used to decrease the immune response and prevent rejection in patients who receive organ or bone marrow transplants.
- 2.2 This medication can be given by the intravenous (IV) or oral (PO) route.

**3 SCOPE AND RESPONSIBILITIES**

- 3.1 Interdisciplinary: Requires an order by a physician or designee in the electronic medical record.
- 3.2 Registered Nurses (RNs) may administer mycophenolate mofetil after successful completion of the medication administration test and demonstration of clinical competency with their preceptor.

**4 DEFINITIONS/ACRONYMS**

- 4.1 GI            Gastrointestinal
- 4.2 IV            Intravenous
- 4.3 PO            Oral
- 4.4 RN            Registered Nurse

**5 MATERIALS**

- 5.1 Primed primary IV administration set.
  - 5.1.1 CellCept is prepared by pharmacy for infusion.
  - 5.1.2 Alcohol prep pad.
  - 5.1.3 Gloves (non-sterile)
  - 5.1.4 Secondary tubing if medication arrives in bag
  - 5.1.5 Closed System Transfusion Device

**6 EQUIPMENT**

- 6.1 Medication administration line.
- 6.2 Volumetric or Syringe Pump.

## **7 SAFETY**

7.1 N/A

## **8 PROCEDURE**

8.1 Patient Assessment:

8.1.1 Assess IV for patency.

8.2 Administration:

8.2.1 Mycophenolate mofetil is to be prepared by pharmacy.

8.2.2 If administered IV a closed system transfer device is needed:

8.2.2.1 Spike the medication bag on secondary tubing and attach to primary IV set.

8.2.2.2 Attach the medication syringe to primary syringe pump tubing.

8.2.2.3 Begin the infusion as ordered. Mycophenolate mofetil is administered IV over 2 hours or as written in the medication order.

8.2.2.4 Notify the physician or designee of any side effects, including, but not limited to, hypotension, temperature greater than (>) 38.5 degrees C, hives, chills, and anaphylaxis.

8.2.2.5 Upon completion of infusion, set pump for the normal saline infusion or D5W flush, as applicable, to insure entire dose has infused.

8.2.3 If administered enteral via tube:

8.2.3.1 Ensure tube is flushed before and after administration.

8.3 Side effects:

8.3.1 The most common side effects associated with Mycophenolate mofetil therapy involve the gastrointestinal (GI) tract, especially diarrhea and vomiting. The reported GI adverse effects occur in greater than (>) 10% of patients and include:

8.3.1.1 nausea/vomiting

8.3.1.2 soft stools and/or diarrhea

8.3.1.3 flatulence

8.3.1.4 abdominal pain

8.3.1.5 constipation

8.3.1.6 dyspepsia

- 8.3.1.7 oral candidiasis
- 8.3.1.8 anorexia
- 8.3.1.9 GI bleeding including peptic ulcer or other GI ulceration and GI perforation
- 8.3.1.10 Colitis, sometimes caused by cytomegalovirus, ischemic colitis, and pancreatitis have been reported
- 8.3.2 Other adverse effects include:
  - 8.3.2.1 generalized pain
  - 8.3.2.2 fever
  - 8.3.2.3 headaches
  - 8.3.2.4 asthenia
  - 8.3.2.5 chest pain
  - 8.3.2.6 elevated hepatic enzymes
  - 8.3.2.7 thrombocytopenia
  - 8.3.2.8 red cell aplasia
  - 8.3.2.9 immunosuppression
  - 8.3.2.10 agranulocytosis
  - 8.3.2.11 back pain
  - 8.3.2.12 hypertension
  - 8.3.2.13 hypotension
  - 8.3.2.14 tachycardia
  - 8.3.2.15 edema
  - 8.3.2.16 hematuria
  - 8.3.2.17 hypercholesterolemia
  - 8.3.2.18 hypokalemia
  - 8.3.2.19 hyperkalemia
  - 8.3.2.20 hyperglycemia
  - 8.3.2.21 hypophosphatemia
  - 8.3.2.22 dyspnea
  - 8.3.2.23 pharyngitis
  - 8.3.2.24 acneiform rash
  - 8.3.2.25 renal tubular necrosis
  - 8.3.2.26 tremor

- 8.3.2.27 insomnia
- 8.3.2.28 sepsis
- 8.3.2.29 dizziness

## **9 RELATED FORMS**

9.1 NA

## **10 REFERENCES**

10.1 2007 THOMPSON MICROMEDEX

## **11 REVISION HISTORY**

| <b>Revision No.</b> | <b>Author</b> | <b>Description of Change(s)</b>  |
|---------------------|---------------|--|
| 07                  | S. McCollum   | - Close system transfer device added to materials section and IV administration. |

## Signature Manifest

**Document Number:** PBMT-GEN-031

**Revision:** 07

**Title:** Administration of Mycophenolate Mofetil Cellcept

**Effective Date:** 27 May 2020

All dates and times are in Eastern Time.

### PBMT-GEN-031 Administration of Mycophenolate Mofetil Cellcept

#### Author

| Name/Signature            | Title | Date                     | Meaning/Reason |
|---------------------------|-------|--------------------------|----------------|
| Sally McCollum (MOORE171) |       | 30 Apr 2020, 02:29:17 PM | Approved       |

#### Medical Director

| Name/Signature              | Title | Date                     | Meaning/Reason |
|-----------------------------|-------|--------------------------|----------------|
| Joanne Kurtzberg (KURTZ001) |       | 30 Apr 2020, 02:53:10 PM | Approved       |

#### Quality

| Name/Signature   | Title | Date                     | Meaning/Reason |
|------------------|-------|--------------------------|----------------|
| Bing Shen (BS76) |       | 04 May 2020, 01:23:55 PM | Approved       |

#### Document Release

| Name/Signature      | Title | Date                     | Meaning/Reason |
|---------------------|-------|--------------------------|----------------|
| Betsy Jordan (BJ42) |       | 05 May 2020, 11:00:24 AM | Approved       |